This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-11. Anything still debated is marked as such rather than presented as settled.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
where S1 is a polypeptide, P1 and P2 are products. The first chemical step (3) includes the formation of a covalent acyl-enzyme intermediate. The second step (4) is the deacylation step. The group H+, initially found on the enzyme, but not in water, appears in the product before the step of hydrolysis, therefore it may be considered as an additional group of the enzymatic reaction. Thus, the reaction (3) shows that the enzyme acts as a powerful reactant of the reaction. According to the proposed concept, the H transport from the enzyme promotes the first reactant conversion, breakdown of the first initial chemical bond (between groups P1 and P2). The step of hydrolysis leads to a breakdown of the second chemical bond and regeneration of the enzyme. The proposed chemical mechanism does not depend on the concentration of the substrates or products in the medium. However, a shift in their concentration mainly causes free energy changes in the first and final steps of the reactions (1) and (2) due to the changes in the free energy content of every molecule, whether S or P, in water solution. This approach is in accordance with the following mechanism of muscle contraction. The final step of ATP hydrolysis in skeletal muscle is the product release caused by the association of myosin heads with actin. The closing of the actin-binding cleft during the association reaction is structurally coupled with the opening of the nucleotide-binding pocket on the myosin active site. Notably, the final steps of ATP hydrolysis include the fast release of phosphate and the slow release of ADP.
Ion-exchange chromatography separates molecules based on their respective charged groups. Ion-exchange chromatography retains analyte molecules on the column based on coulombic (ionic) interactions. The ion exchange chromatography matrix consists of positively and negatively charged ions. Essentially, molecules undergo electrostatic interactions with opposite charges on the stationary phase matrix. The stationary phase consists of an immobile matrix that contains charged ionizable functional groups or ligands. The stationary phase surface displays ionic functional groups (R-X) that interact with analyte ions of opposite charge. To achieve electroneutrality, these immobilized charges couple with exchangeable counterions in the solution. Ionizable molecules that are to be purified, compete with these exchangeable counterions, for binding to the immobilized charges on the stationary phase. These ionizable molecules are retained or eluted based on their charge. Initially, molecules that do not bind or bind weakly to the stationary phase are first to be washed away. Altered conditions are needed for the elution of the molecules that bind to the stationary phase. The concentration of the exchangeable counterions, which competes with the molecules for binding, can be increased, or the pH can be changed to affect the ionic charge of the eluent or the solute. A change in pH affects the charge on the particular molecules and, therefore, alter their binding. When reducing the net charge of the solute's molecules, they start eluting out.
Migraine is a neurological disorder that causes moderate-to-severe headaches. The pain often affects one side of the head, but can affect both. It is generally associated with nausea, light sensitivity and sound sensitivity. Other symptoms may include dizziness, vomiting, and difficulty thinking. In some cases, a migraine attack begins with a period of sensory disturbance known as an aura. Some people experience occasional migraine attacks, while others develop chronic migraine with frequent headaches. Migraine frequency can increase over time. In some cases, frequent use of pain medications can make migraines worse and lead to medication overuse headache. Attacks are more likely to happen when changes occur in a person's daily routine. These triggers can include lack of sleep, disrupted sleep, skipped meals, and hormonal fluctuations. Migraine is believed to result from a combination of genetic, environmental, and neurological factors that affect the activity of nerve cells and chemical signals in the brain. Migraine attacks are theorized to occur when the brain exceeds an individual's sensitivity threshold. Migraine attacks have multiple phases. The initial phase of a migraine attack can start 48 hours before the main headache phase and may cause early warning symptoms. The subsequent pain phase of a migraine attack may be linked to increased activity in the pain pathway of the brain, with heightened blood flow and transmission of pain signals.
=== Cellular implications === A secondary defect in hereditary spherocytosis is a deficiency of membrane surface area. The decrease in surface area leads to less efficient gas exchange of the erythrocyte at the alveoli of the lungs and throughout circulation. Decreased surface area may be produced by two different mechanisms:
Sources: en.wikipedia.org
4-Fluoroselegiline, or p-fluoro-L-deprenyl, is a substituted amphetamine designer drug. It is the enantiopure L- enantiomer of 4-fluorodeprenyl and the 4-fluorinated derivative of selegiline (L-deprenyl).
In particular, Maricopa County has been targeted by conspiracy theorists for alleged irregularities in how the county voted in the 2020 presidential election; the county's ballots were audited by Republicans in 2021, finding no such claims of voter fraud. Ahead of the 2023 Philadelphia mayoral election and the Pennsylvania primary election, the account for the Philadelphia City Commissioners was unverified, leading to several verified accounts impersonating the commissioners. On May 22, an account aligned with the QAnon conspiracy theory posted an image generated by artificial intelligence that seemingly depicted an explosion near the Pentagon. The fake image was amplified by the Russian propaganda television network RT and the far-right blog Zero Hedge. A verified account posing as Bloomberg News then posted the claim accompanied by several other verified accounts. The S&P 500 fell sharply as a result of the news before rebounding. Several Indian news outlets, including Zee News and Republic TV, aired false reports about the supposed explosion.
Features of the Initial Lesion: Vasculitis of vessels subjacent to junctional epithelium Increased migration of leukocytes into junctional epithelium Extravascular presence of serum proteins, especially fibrin Alteration of the most coronal portion of junctional epithelium Loss of perivascular collagen
Sources: en.wikipedia.org
In plants, injuries result from the consumption of plant parts by herbivorous animals, including insects and mammals, from damage to tissues by plant pathogens such as bacteria and fungi, which may gain entry after herbivore damage or in other ways, and from abiotic factors such as heat, freezing, flooding, lightning, and pollutants such as ozone. Plants respond to injury by signalling that damage has occurred, secreting materials that seal off the damaged area, producing antimicrobial chemicals, and, in woody plants, regrowing over wounds.
== See also == International relations since 1989 Iran–Saudi Arabia proxy conflict Iran–Israel proxy conflict Artificial intelligence arms race Arms race Nuclear arms race Digital Revolution Postmodernism Cold peace Interwar period Road to Now Ongoing armed conflicts
== Liquids or solvents == In many cases, the presence of water can prevent a reaction from happening, or cause undesirable products to form. To prevent this, anhydrous solvents must be used when performing certain reactions. Examples of reactions requiring the use of anhydrous solvents are the Grignard reaction and the Wurtz reaction. Solvents have typically been dried using distillation or by reaction with reactive metals or metal hydrides. These methods can be dangerous and are a common cause of lab fires. More modern techniques include the use of molecular sieves or a column purification system. Molecular sieves are far more effective than most common methods for drying solvents and are safer and require no special equipment for handling. Column solvent purification devices (generally referred to as Grubb's columns) recently became available, reducing the hazards (water reactive substances, heat) from the classical dehydrating methods. Anhydrous solvents are commercially available from chemical suppliers, and are packaged in sealed containers to maintain dryness. Typically anhydrous solvents will contain approximately 10 ppm of water and will increase in wetness if they are not properly stored. Organic solutions can be dried using a range of drying agents. Typically following a workup the organic extract is dried using magnesium sulfate or a similar drying agent to remove most remaining water. Anhydrous acetic acid is known as glacial acetic acid.
From 1948 to 1994, international rugby relations with apartheid South Africa, and also the non-integrated nature of rugby within the country drew frequent controversy. South Africa remained a member of the International Rugby Board (IRB) throughout the apartheid era. Halt All Racist Tours was established in New Zealand in 1969 to oppose continued tours to and from South Africa. Though contacts were restricted after the Gleneagles Agreement in 1977, there were controversial tours in 1980 by the British Lions and by France, in 1981 by Ireland, and in 1984 by England. South Africa toured New Zealand in 1981. South Africa were excluded from the first two Rugby World Cups, in 1987 and 1991. Racially selected New Zealand sports teams toured South Africa until the 1970 All Blacks rugby tour allowed Māori to go under the status of 'honorary whites'. The issue affected not only black South Africans, but also indigenous New Zealanders and to a lesser extent indigenous Australians. Many major rugby union international sides had few non-white players, but theoretically, a side such as Fiji would have been frowned upon. Apartheid South Africa's last foreign tour was to New Zealand in 1981, prior to the system's dismantlement in 1991 and new elections in 1994.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.